Neucardin: Interim Phase II data

Interim data from a double-blind, U.S. Phase II trial in 67 CHF patients showed that 2 doses of 8-hour subcutaneous Neucardin for 10 days met the primary endpoint of improving LVEF from baseline to 30 days vs. placebo (placebo-corrected improvement of 3-5%, p<0.05). Neucardin

Read the full 446 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE